ArticleCancer reports (Hoboken, N.J.)2023

Anlotinib plus camrelizumab achieved long-term survival in a patient with metastatic esophageal neuroendocrine carcinoma.

Lingxiao Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.